A new study has shown that antidepressant fluvoxamine can stop the worsening of symptoms of COVID-19, the University of Washington reports.
Fluvoxamine is likely to prevent the exacerbation of COVID-19 infections and avoid hospitalization. In a clinical trial, fluvoxamine was compared to placebo in 152 adult outpatients infected with coronavirus. None of the participants who received fluvoxamines experienced “clinical deterioration” after 15 days, unlike six patients who received placebo. Of these six patients, four were hospitalized for periods of 4 to 21 days. One was on artificial lung ventilation for 10 days.
Although the study was small, the researchers say the results are statistically significant and fluvoxamine requires further study as a cure for COVID-19. They plan to launch a larger trial in the next few weeks.
“As elevated levels of cytokines are associated with the seriousness of COVID-19, testing fluvoxamine in clinical trials makes great sense,” say the leading authors.